JP2005500357A5 - - Google Patents

Download PDF

Info

Publication number
JP2005500357A5
JP2005500357A5 JP2003517072A JP2003517072A JP2005500357A5 JP 2005500357 A5 JP2005500357 A5 JP 2005500357A5 JP 2003517072 A JP2003517072 A JP 2003517072A JP 2003517072 A JP2003517072 A JP 2003517072A JP 2005500357 A5 JP2005500357 A5 JP 2005500357A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
glucosyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003517072A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005500357A (ja
JP4679055B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/023553 external-priority patent/WO2003011881A2/en
Publication of JP2005500357A publication Critical patent/JP2005500357A/ja
Publication of JP2005500357A5 publication Critical patent/JP2005500357A5/ja
Application granted granted Critical
Publication of JP4679055B2 publication Critical patent/JP4679055B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003517072A 2001-07-27 2002-07-24 ヒドロモルホン、ジヒドロモルフィンおよびジヒドロイソモルフィンの糖誘導体、これらの組成物および痛みを治療あるいは予防するための使用 Expired - Fee Related JP4679055B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30784501P 2001-07-27 2001-07-27
PCT/US2002/023553 WO2003011881A2 (en) 2001-07-27 2002-07-24 Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain

Publications (3)

Publication Number Publication Date
JP2005500357A JP2005500357A (ja) 2005-01-06
JP2005500357A5 true JP2005500357A5 (enExample) 2006-01-05
JP4679055B2 JP4679055B2 (ja) 2011-04-27

Family

ID=23191416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003517072A Expired - Fee Related JP4679055B2 (ja) 2001-07-27 2002-07-24 ヒドロモルホン、ジヒドロモルフィンおよびジヒドロイソモルフィンの糖誘導体、これらの組成物および痛みを治療あるいは予防するための使用

Country Status (14)

Country Link
US (1) US6740641B2 (enExample)
EP (1) EP1412368B1 (enExample)
JP (1) JP4679055B2 (enExample)
AT (1) ATE371665T1 (enExample)
AU (1) AU2002329634B2 (enExample)
CA (1) CA2455774C (enExample)
CY (1) CY1107813T1 (enExample)
DE (1) DE60222137T2 (enExample)
DK (1) DK1412368T3 (enExample)
ES (1) ES2292806T3 (enExample)
IL (2) IL160085A0 (enExample)
MX (1) MXPA04000825A (enExample)
PT (1) PT1412368E (enExample)
WO (1) WO2003011881A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2005032474A2 (en) * 2003-09-30 2005-04-14 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US7659253B2 (en) * 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
EP1531844B1 (en) * 2002-02-22 2014-08-20 Shire LLC Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
KR20050010756A (ko) * 2002-02-22 2005-01-28 뉴 리버 파마슈티칼스, 인크. 피험자 간 약물 혈청 농도의 변동성을 감소시키기 위한펩티드-약물 접합체의 용도
GB0218811D0 (en) * 2002-08-14 2002-09-18 Cenes Ltd Salts of morphine-6-glucuronide
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
NZ544162A (en) * 2003-05-29 2008-09-26 Shire Llc Abuse resistant amphetamine compounds
KR101453107B1 (ko) * 2006-04-21 2014-10-27 디에스엠 아이피 어셋츠 비.브이. 오피오이드 수용체 길항제의 용도
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
FR2939436B1 (fr) * 2008-12-10 2010-12-17 Sanofi Aventis Synthese de morphine-6-glucuronide ou de l'un de ses derives
WO2011126910A2 (en) 2010-03-30 2011-10-13 Algynomics Inc. Compositions and methods for the treatment of somatosensory disorders
US8716350B2 (en) * 2010-03-30 2014-05-06 Algynomics Inc. Compositions and methods for the treatment of somatosensory disorders
MX2013003354A (es) 2010-09-21 2013-06-24 Purdue Pharma Lp Analogos de buprenorfina.
SG11201401856VA (en) 2011-10-26 2014-05-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
EP3333156A3 (en) 2012-11-09 2018-09-26 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US9175000B2 (en) 2012-12-07 2015-11-03 Purdue Pharma L.P. Buprenorphine analogs
TWI513697B (zh) 2012-12-14 2015-12-21 Purdue Pharma Lp 吡啶酮並嗎啡喃類似物及其對類鴉片受體之生物活性
WO2014091297A1 (en) 2012-12-14 2014-06-19 Purdue Pharma L.P. Spirocyclic morphinans and their use
US9056836B2 (en) 2013-01-31 2015-06-16 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
EP3087078B1 (en) 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
EP3087079B1 (en) 2013-12-26 2019-04-03 Purdue Pharma LP Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
EP3087073B1 (en) 2013-12-26 2018-07-04 Purdue Pharma LP 10-substituted morphinan hydantoins
AU2014370062A1 (en) 2013-12-26 2016-08-11 Purdue Pharma L.P. Ring-contracted morphinans and the use thereof
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
US10550088B2 (en) 2013-12-27 2020-02-04 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
JP2017521373A (ja) 2014-05-27 2017-08-03 パーデュー、ファーマ、リミテッド、パートナーシップ スピロ環モルフィナン及びその使用
EP3154972A4 (en) 2014-06-13 2017-11-22 Purdue Pharma L.P. Azamophinan derivatives and use thereof
NZ731586A (en) 2014-12-02 2018-06-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
ITUB20154996A1 (it) 2015-10-27 2017-04-27 Nobili S P A Attrezzatura per l?erogazione di un liquido di trattamento ad una rispettiva coltura o piantagione agricola.
MX2019001224A (es) 2016-07-29 2019-06-03 Janssen Pharmaceutica Nv Metodos para tratar el cancer de prostata.
US10745402B2 (en) 2017-01-02 2020-08-18 Purdue Pharma L.P. Morphinan derivatives and use thereof
WO2020012245A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
WO2020012248A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Novel naphthylenyl compounds for long-acting injectable compositions and related methods
WO2020094634A1 (en) 2018-11-05 2020-05-14 Alkermes Pharma Ireland Limited Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods
EP4577667A2 (en) * 2022-08-25 2025-07-02 Biosynth GmbH Procedure for production of opioid-antagonist-releasing compounds and their use as a medicine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2058243T3 (es) 1988-01-12 1994-11-01 Baker Norton Pharma Derivados del acido glucuronico de antagonistas de opiaceos.
FR2680786B1 (fr) * 1991-09-04 1995-03-10 Irepa Procede de synthese de glucuronides d'epoxy-4,5 morphinanes.
EP0816375A1 (en) * 1995-11-29 1998-01-07 Rolabo Sl Glycoconjugates of opiated substances
GB9711118D0 (en) 1997-05-29 1997-07-23 Rolabo Sl Compound

Similar Documents

Publication Publication Date Title
JP2005500357A5 (enExample)
JP2003503454A5 (enExample)
JP2006504723A5 (enExample)
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
DE60222137D1 (de) Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
GB0022438D0 (en) Organic Compounds
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
CY1111615T1 (el) Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους.
JP2006514116A5 (enExample)
NZ605469A (en) Nalbuphine-based formulations and uses thereof
JP2006500346A5 (enExample)
ES2139673T3 (es) Utilizacion de norastemizol para el tratamiento de rinitis alergica.
JP2003526626A5 (enExample)
TW200624431A (en) Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
JP2005507892A5 (enExample)
RU2003118411A (ru) Кристаллические производные 1-метилкарбапенема
JP2008513510A5 (enExample)
WO2007038112A3 (en) Combination of rosiglitazone and donepezil for improvement of cognitive function
MY133527A (en) Isoquinoline derivatives
ATE406897T1 (de) Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs
JP2010500284A5 (enExample)
RU2006113366A (ru) Терапевтическое лечение
JP2008513426A5 (enExample)
JP2005513036A5 (enExample)
JP2009516719A5 (enExample)